BUSINESSCNBC TOP
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are competing to enter the obesity drug market currently dominated by Novo Nordisk and Eli Lilly. The article highlights the pharmaceutical industry's interest in this lucrative sector.
Related Signal
Adjacent reporting
- An obesity drug deep-dive, and peptides move mainstream
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
- Novo Nordisk partners with OpenAI in weight loss drug race
- STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
- Hims Sales Miss on Rising Competition for Weight-Loss Drugs